The majority of patients with early-stage disease Alzheimer’s disease (AD) had stable or improved cognition over roughly 1 year of treatment with lecanemab (Leqembi), a real-world analysis showed. The ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback